RETRACTED: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease (Retracted Article)

被引:21
作者
Delbaldo, Catherine [1 ]
Michiels, Stefan [1 ]
Rolland, Estelle [1 ]
Syz, Nathalie [1 ]
Soria, Jean-Charles [1 ]
Le Chevalier, Thierry [1 ]
Pignon, Jean-Pierre [1 ]
机构
[1] Inst Gustave Roussy, Serv Biostat Epidemiol, F-94805 Villejuif, France
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2007年 / 04期
关键词
D O I
10.1002/14651858.CD004569.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Randomized trials have demonstrated that adding a drug to a single-agent or to a two-agent regimen increased the tumor response rate in patients with advanced non-small cell lung cancer (NSCLC), although its impact on survival remains controversial. Objectives To evaluate the clinical benefit of adding a drug to a single-agent or two-agent chemotherapy regimen in terms of tumor response rate, survival, and toxicity in patients with advanced NSCLC. Search strategy There were no language restrictions. Searches of MEDLINE and EMBASE were performed using the search terms non-small cell lung carcinoma/drug therapy, adenocarcinoma, large-cell carcinoma, squamous-cell carcinoma, lung, neoplasms, clinical trial phase III, and randomized trial. Manual searches were also performed to find conference proceedings published between January 1982 and June 2006. Selection criteria Data from all randomized controlled trials performed between 1980 and 2006 (published between January 1980 and June 2006) comparing a doublet regimen with a single-agent regimen or comparing a triplet regimen with a doublet regimen in patients with advanced NSCLC. Data collection and analysis Two independent investigators reviewed the publications and extracted the data. Pooled odds ratios (ORs) for the objective tumor response rate, one-year survival rate, and toxicity rate were calculated using the fixed-effect model. Pooled median ratios (MRs) for median survival also were calculated using the fixed-effect model. ORs and MRs lower than unity (< 1.0) indicate a benefit of a doublet regimen compared with a single-agent regimen (or a triplet regimen compared with a doublet regimen). Main results Sixty-five trials (13601 patients) were eligible. In the trials comparing a doublet regimen with a single-agent regimen, a significant increase was observed in tumor response (OR 0.42, 95% confidence interval [CI] 0.37 to 0.47, P < 0.001) and one-year survival (OR 0.80, 95% CI 0.70 to 0.91, P < 0.001) in favor of the doublet regimen. The median survival ratio was 0.83 ( 95% CI 0.79 to 0.89, P < 0.001). An increase also was observed in the tumor response rate (OR 0.66, 95% CI 0.58 to 0.75, P < 0.001) in favor of the triplet regimen, but not for one-year survival (OR 1.01, 95% CI 0.85 to 1.21, P = 0.88). The median survival ratio was 1.00 (95% CI 0.94 to 1.06, P = 0.97). Authors' conclusions Adding a second drug improved tumor response and survival rate. Adding a third drug had a weaker effect on tumor response and no effect on survival.
引用
收藏
页数:49
相关论文
共 166 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]   Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer:: A Spanish lung cancer group phase III randomized trial [J].
Alberola, V ;
Camps, C ;
Provencio, M ;
Isla, D ;
Rosell, R ;
Vadell, C ;
Bover, I ;
Ruiz-Casado, A ;
Azagra, P ;
Jiménez, U ;
González-Larriba, JL ;
Diz, P ;
Cardenal, F ;
Artal, A ;
Carrato, A ;
Morales, S ;
Sánchez, JJ ;
de las Peñas, R ;
Felip, E ;
López-Vivanco, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3207-3213
[3]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[4]  
[Anonymous], [No title captured]
[5]  
ARECO A, 1989, P AN M AM SOC CLIN, V8, P240
[6]  
BAGGSTROM MQ, 2003, P AN M AM SOC CLIN, V22, P624
[7]  
BAGGSTROM MQ, 2002, P AN M AM SOC CLIN, V21, pA306
[8]   Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study [J].
Baldini, E ;
Tibaldi, C ;
Ardizzoni, A ;
Salvati, F ;
Antilli, A ;
Portalone, L ;
Barbera, S ;
Romano, F ;
De Marinis, F ;
Migliorino, MR ;
Noseda, MA ;
Borghini, U ;
Crippa, M ;
Ferrara, G ;
Raimondi, M ;
Fioretti, M ;
Bandera, M ;
Pennucci, MC ;
Galeasso, G ;
Cacciani, GC ;
Lepidini, G ;
Sunseri, G ;
Lanfranco, C ;
Rinaldi, M ;
Lionetto, R ;
Conte, PF ;
Rosso, R .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2367-2370
[9]  
Bando H, 1986, Gan To Kagaku Ryoho, V13, P2094
[10]  
BERARDI R, 2001, P AN M AM SOC CLIN, V20, pA347